Allergen Challenge Chamber Study With Single Dose Oral GSK835726 Compared With Placebo
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
A randomised, double-blind, placebo-controlled, 4-period incomplete block crossover study of
single oral dose GSK835726 (100mg, 50mg, 10mg), Cetirizine (10mg) and placebo to evaluate the
efficacy and safety using an Environmental challenge chamber in male subjects with seasonal
allergic rhinitis